PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。主要目的是：确定原发性胆管和胆囊肿瘤患者联合使用曲平和吉西他滨的客观缓解率；评估曲平和吉西他滨联合治疗胆管和胆囊肿瘤患者的毒性和毒性恢复情况；确定曲平和吉西他滨联合治疗胆道和胆囊肿瘤患者的生存期和无进展生存期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives are to: determine the objective response rates for the combination of triapine and gemcitabine in patients with primary tumors of the biliary ducts and gall bladder; assess the toxicities and recovery from toxicities for patients with biliary duct and gall baldder tumors treated with the combination of triapine and gemcitabine; and determine the survival and progression free survival of patients with biliary and gall bladder tumors treated with combination of triapine and gemcitabine.